P27KIP1 is involved in ERK1/2-mediated MMP-9 expression via the activation of NF-κB binding in the IL-7-induced migration and invasion of 5637 cells

International Journal of Oncology

Volumn 44, Issue 4, 2014, Pages 1349-1356

  Park, Sung Lyea ^a   Lee, Eo Jin ^b   Kim, Wun Jae ^b   Moon, Sung Kwon ^a  

^a Chung Ang University   (South Korea)

^b Chungbuk National University   (South Korea)

Author keywords

Bladder cancer cells; IL 7; Invasion; Migration; p27KIP1

Indexed keywords

CDKN1B PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; GELATINASE B; IL7 PROTEIN, HUMAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 7; MITOGEN ACTIVATED PROTEIN KINASE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR AP 1;

BIOSYNTHESIS; BLADDER TUMOR; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; PATHOLOGY; PHOSPHORYLATION; RNA INTERFERENCE; TUMOR CELL LINE; TUMOR INVASION; WOUND HEALING;

CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; INTERLEUKIN-7; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; NF-KAPPA B; PHOSPHORYLATION; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSCRIPTION FACTOR AP-1; URINARY BLADDER NEOPLASMS; WOUND HEALING;

EID: 84894427129     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2290     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007. (Pubitemid 46148091)
2. Levi F, La Vecchia C, Randimbison L and Franceschi S: Incidence of infiltrating cancer following superficial bladder carcinoma. Int J Cancer 55: 419-554, 1993.
3. Black PC and Dinney CP: Bladder cancer angiogenesis and metastasis - translation from murine model to clinical trial. Cancer Metastasis Rev 26: 623-634, 2007. (Pubitemid 350115114)
4. Matrisian LM: Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 6: 121-125, 1990.
5. Liotta LA: Tumor invasion and metastasis-role of extracellular matrix: Rhoads Memorial Award Lecture. Cancer Res 46: 1-7, 1986.
6. Bond M, Rosalind P, Fabunmi P, Baker AH and Newby AC: Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Lett 435: 29-34, 1998. (Pubitemid 28432009)
7. Sato H and Seiki M: Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 8: 395-405, 1993. (Pubitemid 23073756)
8. Lee SJ, Cho SC, Lee EJ, Kim S, Lee SB, Lim JH, Choi YH, Kim WJ and Moon SK: Interleukin-20 promotes migration of bladder cancer cells through extracellular signal-regulated kinase (ERK)-mediated MMP-9 protein expression leading to nuclear factor (NF-κB) activation by inducing the up-regulation of p21(WAF1) protein expression. J Biol Chem 288: 5539-5552, 2013.
9. Moon SK, Cha BY and Kim CH: ERK1/2 mediates TNF-alpha-induced matrix metalloproteinase-9 expression in human vascular smooth muscle cells via the regulation of NF-kappaB and AP-1: involvement of the ras dependent pathway. J Cell Physiol 198: 417-427, 2004. (Pubitemid 38235037)
10. Sato H, Kita M and Seiki M: v-Src activates the expression of 92-kDa type IV collagenase gene through the AP-1 site and the GT box homologous to retinoblastoma control elements. A mechanism regulating gene expression independent of that by inflammatory cytokines. J Biol Chem 268: 23460-23468, 1993. (Pubitemid 23328072)
11. Nicosia SV, Bai W, Cheng JQ, Coppola D and Kruk PA: Oncogenic pathways implicated in ovarian epithelial cancer. Hematol Oncol Clin North Am 17: 927-943, 2003. (Pubitemid 37022149)
12. Cho A, Graves J and Reidy MA: Mitogen-activated protein kinases mediate matrix metalloproteinase-9 expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 20: 2527-2532, 2000.
13. Yao J, Xiong S, Klos K, Nguyen N, Grijalva R, Li P and Yu D: Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-beta1 in human breast cancer cells. Oncogene 20: 8066-8074, 2001. (Pubitemid 34028331)
14. Kittipatarin C and Khaled AR: Interlinking interleukin-7. Cytokine 39: 75-83, 2007. (Pubitemid 47446258)
15. Jiang Q, Li WQ, Aiello FB, Mazzucchelli R, Asefa B, Khaled AR and Durum SK: Cell biology of IL-7, a key lymphotrophin. Cytokine Growth Factor Rev 16: 513-533, 2005. (Pubitemid 41022015)
16. Mian BM, Dinney CP, Bermejo CE, Sweeney P, Tellez C, Yang XD, Gudas JM, McConkey DJ and Bar-Eli M: Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB. Clin Cancer Res 9: 3167-3175, 2003. (Pubitemid 36993279)
17. Sier CF, Casetta G, Verheijen JH, Tizzani A, Agape V, Kos J, Blasi F and Hanemaaijer R: Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers. Clin Cancer Res 6: 2333-2340, 2000. (Pubitemid 30399200)
18. Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T, Neal D, Thomas D, Hanby A and Balkwill F: Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res 53: 5365-5369, 1993. (Pubitemid 23342150)
19. Nutt JE, Durkan GC, Mellon JK and Lunec J: Matrix metalloproteinases (MMPs) in bladder cancer: the induction of MMP9 by epidermal growth factor and its detection in urine. BJU Int 91: 99-104, 2003.
20. Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC and Freeman MR: Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res 58: 1395-1399, 1998. (Pubitemid 28193598)
21. Di Carlo A, Terracciano D, Mariano A and Macchia V: Urinary gelatinase activities (matrix metalloproteinases 2 and 9) in human bladder tumors. Oncol Rep 15: 1321-1326, 2006.
22. Fleming HE and Paige CJ: Pre-B cell receptor signaling mediates selective response to IL-7 at the pro-B to pre-B cell transition via an ERK/MAP kinase-dependent pathway. Immunity 15: 521-531, 2001. (Pubitemid 33016438)
23. Crawley JB, Rawlinson L, Lali FV, Page TH, Saklatvala J and Foxwell BM: T cell proliferation in response to interleukins 2 and 7 requires p38MAP kinase activation. J Biol Chem 272: 15023-15027, 1997. (Pubitemid 27251779)
24. Reddy KB, Nabha SM and Atanaskova N: Role of MAP kinase in tumor progression and invasion. Cancer Metastasis Rev 22: 395-403, 2003. (Pubitemid 36791895)
25. Li WQ, Jiang Q, Aleem E, Kaldis P, Khaled AR and Durum SK: IL-7 promotes T cell proliferation through destabilization of p27Kip1. J Exp Med 203: 573-582, 2006.
26. Barata JT, Cardoso AA, Nadler LM and Boussiotis VA: Interleukin-7 promotes survival and cell cycle progression of T-cell acute lymphoblastic leukemia cells by down-regulating the cyclin-dependent kinase inhibitor p27(kip1). Blood 98: 1524-1531, 2001.
27. Hofmeister R, Khaled AR, Benbernou N, Rajnavolgyi E, Muegge K and Durum SK: Interleukin-7: physiological roles and mechanisms of action. Cytokine Growth Factor Rev 10: 41-60, 1999. (Pubitemid 29230851)
28. Coussens LM and Werb Z: Inflammation and cancer. Nature 420: 860-867, 2002. (Pubitemid 36019639)
29. Dranoff G: Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 4: 11-22, 2004.
30. Goswami B, Rajappa M, Sharma M and Sharma A: Inflammation: its role and interplay in the development of cancer, with special focus on gynecological malignancies. Int J Gynecol Cancer 18: 591-599, 2008. (Pubitemid 352020177)
31. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM and Pagano M: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 3: 231-234, 1997. (Pubitemid 27064711)
32. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI and Slingerland JM: Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 3: 227-230, 1997. (Pubitemid 27064710)
33. Shariat SF, Zlotta AR, Ashfaq R, Sagalowsky AI and Lotan Y: Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod Pathol 20: 445-459, 2007. (Pubitemid 46482368)